ACIP issues recommendations for Lyme disease vaccine. Advisory Committee on Immunization Practices.
Morey
S S
SS
D000954:Antigens, Surface / Q000627:therapeutic use*; D001425:Bacterial Outer Membrane Proteins / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D015748:Borrelia burgdorferi Group / Q000187:drug effects*; D002487:Centers for Disease Control and Prevention, U.S.; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008074:Lipoproteins / Q000627:therapeutic use; D008193:Lyme Disease / Q000276:immunology / Q000517:prevention & control*; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012306:Risk; D012307:Risk Factors; D014481:United States
D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein; D011994:Recombinant Proteins